CorMedixCRMD
CRMD
About: Cormedix Inc is a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions. The Company's focus is on the commercialization of its product, DefenCath, in the United States (U.S.) and other key markets. The group currently operates in a single segment, Drug Product, located in a single geographic location, the United States.
Employees: 82
0
Funds holding %
of 7,312 funds
0
Analysts bullish %
of 3 analysts
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
65% more first-time investments, than exits
New positions opened: 28 | Existing positions closed: 17
44% more repeat investments, than reductions
Existing positions increased: 49 | Existing positions reduced: 34
5% more funds holding
Funds holding: 129 [Q4 2024] → 136 (+7) [Q1 2025]
0% more funds holding in top 10
Funds holding in top 10: 1 [Q4 2024] → 1 (+0) [Q1 2025]
1.41% less ownership
Funds ownership: 37.83% [Q4 2024] → 36.42% (-1.41%) [Q1 2025]
19% less call options, than puts
Call options by funds: $4.77M | Put options by funds: $5.89M
21% less capital invested
Capital invested by funds: $186M [Q4 2024] → $146M (-$39.7M) [Q1 2025]
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$17
52%
upside
Avg. target
$19
69%
upside
High target
$20
78%
upside
3 analyst ratings
3 positive
100%
0 neutral
0%
0 negative
0%
HC Wainwright & Co. Brandon Folkes | 78%upside $20 | Buy Initiated | 30 Jun 2025 |
Needham Serge Belanger | 78%upside $20 | Buy Maintained | 24 Jun 2025 |
RBC Capital Leonid Timashev | 52%upside $17 | Outperform Reiterated | 20 Jun 2025 |
Financial journalist opinion
Based on 8 articles about CRMD published over the past 30 days
Positive
Benzinga
1 week ago
CorMedix Analyst Says Investors Could Be Further Rewarded
Last week, CorMedix Inc. CRMD said one of its large dialysis organization (LDO) customers has started ordering, with implementation planned for the second half of 2025.
Positive
Seeking Alpha
1 week ago
CorMedix Seems Significantly Undervalued
CorMedix offers high upside potential with DefenCath, the only FDA-approved catheter lock solution for CRBSI, and a strong financial position. My DCF model shows a base-case fair value of $26.2 per share, representing 110% upside; the options market also signals bullish sentiment. Key risks include reliance on a single product and high market share uncertainty, so I keep my position size small and avoid options due to illiquidity and high premiums.
Negative
Benzinga
2 weeks ago
Concentrix Posts Downbeat Earnings, Joins CorMedix And Other Big Stocks Moving Lower In Friday's Pre-Market Session
U.S. stock futures were higher this morning, with the Dow futures gaining over 100 points on Friday.
Neutral
GlobeNewsWire
2 weeks ago
CorMedix Inc. Announces Pricing of Public Offering of Common Stock
BERKELEY HEIGHTS, N.J., June 27, 2025 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced the pricing of its previously announced underwritten public offering of 6,604,507 shares of its common stock. The total gross proceeds from the offering to the Company are expected to be approximately $85 million. In addition, CorMedix granted the underwriters a 30-day option to purchase up to an additional 15% of the shares of its common stock offered in the offering. The closing of the offering is expected to occur on or about June 30, 2025, subject to the satisfaction of customary closing conditions.
Neutral
GlobeNewsWire
2 weeks ago
CorMedix Inc. Announces Proposed Public Offering of Common Stock
BERKELEY HEIGHTS, N.J., June 26, 2025 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced that it intends to offer and sell $85.0 million of shares of its common stock in an underwritten public offering. All of the shares to be sold in the offering will be offered by CorMedix. In addition, CorMedix intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of its common stock offered in the public offering, at the public offering price, less underwriting discounts and commissions. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
Positive
Zacks Investment Research
2 weeks ago
Strength Seen in CorMedix (CRMD): Can Its 21.7% Jump Turn into More Strength?
CorMedix (CRMD) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Positive
Investors Business Daily
2 weeks ago
CorMedix Spikes To Four-Year High On A Surprise Deal For Its Leading Drug
CorMedix shares bounded to a four-year high Monday after the biotech company inked an expanded deal for its leading drug, DefenCath.
Neutral
GlobeNewsWire
2 weeks ago
CorMedix inc. Announces Customer Implementation
BERKELEY HEIGHTS, N.J., June 23, 2025 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announces an update related to its Large Dialysis Organization (LDO) customer and planned implementation in the second half of 2025.
Positive
Seeking Alpha
1 month ago
CorMedix: DefenCath In Exponential Growth Phase With Robust Market Position
I am bullish on CorMedix due to its strong financial turnaround, robust revenue growth, and unique market position. DefenCath, the only FDA-approved antimicrobial catheter lock solution in the US, drives exponential revenue and profitability, with high adoption potential. CRMD's competitive edge lies in its first-mover advantage, high efficacy, and significant penetration in the US dialysis market.
Positive
Seeking Alpha
1 month ago
CorMedix: Exceeding Expectations
CorMedix and its flagship product DefenCath have significantly outperformed expectations since commercialization, driving strong stock performance in 2025. DefenCath, approved just over a year ago, is proving highly effective in reducing catheter-related bloodstream infections, supporting its 'best of breed' status. Recent Q1 results beat consensus estimates, and the stock has strong analyst support and some recent upwardly revised price targets, reflecting confidence in continued growth.
Charts implemented using Lightweight Charts™